Q3 Earnings Forecast for Neurogene Issued By HC Wainwright

Key Points

• HC Wainwright lowered its Q3 2026 EPS estimate for Neurogene to a loss of $1.36 per share from $1.34, while maintaining a Buy rating and a $65 price target.
• Neurogene reported a Q2 loss of $1.53 per share, missing the consensus estimate of a $1.42 loss. Analysts remain moderately bullish, with a consensus price target of $83.67.
• Shares opened at $35.63, down 3.7%, while institutional ownership stands at 52.37%; BlackRock and Deutsche Bank were among investors initiating new positions during the second quarter.

Neurogene Inc. (NASDAQ:NGNE - Free Report) - Investment analysts at HC Wainwright reduced their Q3 2026 earnings estimates for Neurogene in a research report issued to clients and investors on Wednesday, August 12th. HC Wainwright analyst M. Kapoor now expects that the company will post earnings per share of ($1.36) for the quarter, down from their prior estimate of ($1.34). HC Wainwright currently has a "Buy" rating and a $65.00 price target on the stock. The consensus estimate for Neurogene's current full-year earnings is ($5.63) per share. HC Wainwright also issued estimates for Neurogene's Q4 2026 earnings at ($1.20) EPS, FY2026 earnings at ($5.44) EPS, Q1 2027 earnings at ($1.22) EPS, Q2 2027 earnings at ($1.24) EPS, Q3 2027 earnings at ($1.26) EPS, Q4 2027 earnings at ($1.27) EPS and FY2027 earnings at ($4.99) EPS.

Neurogene (NASDAQ:NGNE - Get Free Report) last released its earnings results on Tuesday, August 11th. The company reported ($1.53) EPS for the quarter, missing analysts' consensus estimates of ($1.42) by ($0.11).

Several other equities analysts have also commented on NGNE. Weiss Ratings restated a "sell (d-)" rating on shares of Neurogene in a research note on Friday, July 17th. Guggenheim boosted their price objective on shares of Neurogene from $69.00 to $81.00 and gave the stock a "buy" rating in a research note on Wednesday. Rodman & Renshaw started coverage on Neurogene in a research report on Wednesday, June 3rd. They issued a "buy" rating and a $70.00 price objective for the company. UBS Group set a $70.00 price objective on shares of Neurogene in a research report on Wednesday, June 3rd. Finally, Canaccord Genuity Group reduced their target price on Neurogene from $180.00 to $166.00 and set a "buy" rating for the company in a research note on Wednesday. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $83.67.

Neurogene Trading Down 3.7%

Neurogene stock opened at $35.63 on Friday. The firm has a 50-day moving average price of $33.92 and a 200-day moving average price of $26.83. Neurogene has a 12-month low of $15.93 and a 12-month high of $43.66. The firm has a market capitalization of $712.96 million, a PE ratio of -7.08 and a beta of 1.70.

Insider Buying and Selling at Neurogene

In other Neurogene news, CFO Christine Mikail Cvijic sold 4,200 shares of the business's stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $36.13, for a total transaction of $151,746.00. Following the transaction, the chief financial officer owned 84,040 shares of the company's stock, valued at approximately $3,036,365.20. The trade was a 4.76% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 9,600 shares of company stock valued at $339,932 over the last quarter. Company insiders own 11.68% of the company's stock.

Hedge Funds Weigh In On Neurogene

Institutional investors and hedge funds have recently made changes to their positions in the stock. BlackRock Inc. purchased a new position in Neurogene in the second quarter valued at approximately $33,274,000. Deutsche Bank AG purchased a new stake in shares of Neurogene in the second quarter valued at about $3,354,000. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in shares of Neurogene in the 2nd quarter valued at approximately $192,000. Bank of New York Mellon Corp acquired a new stake in shares of Neurogene in the 2nd quarter worth $904,000. Finally, State of Wyoming purchased a new position in shares of Neurogene during the 2nd quarter worth approximately $31,000. 52.37% of the stock is owned by institutional investors and hedge funds.

Neurogene Company Profile

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company's lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene's pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene's proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source